Navigation Links
Scientists Spot Real 'Smoking Gun' in Prostate Cancer
Date:5/21/2010

Gene fusion may be behind disease, not androgen receptors, study suggests

FRIDAY, May 21 (HealthDay News) -- The primary cause of prostate cancer could be the fusion of two genes and the subsequent abnormal prostate cell growth that results when receptors for the hormone androgen get blocked, a new study reveals.

The implication is that standard efforts to treat the disease by targeting the androgen receptors might be missing the real "smoking gun," a University of Michigan Comprehensive Cancer Center team suggests.

"We need to begin to think about targeting prostate cancer by targeting the gene fusion, and not confining our approaches to androgen receptors," study author Dr. Arul Chinnaiyan, director of the Michigan Center for Translational Pathology, said in a news release. "If we're going to find a more durable therapy, we need to get at the gene fusion."

Chinnaiyan and his colleagues report their findings in the May 18 issue of Cancer Cell.

The authors note that typical prostate cancer treatments focus on drugs that attempt to slow production of androgen, the male hormone that regulates healthy prostate growth. However, such efforts usually become less effective over time as cancer cell resistance mounts, making recurrent cancer much less amenable to similar treatments.

But having earlier identified a so-called "on switch" for prostate cancer development in the form of the initial fusion of a prostate gene with a cancer-causing gene, Chinnaiyan and colleagues now have launched a new investigation into what happens post-fusion.

By using high-tech genetic mapping techniques, the research team found that once fusion takes place, androgen receptors get blocked, in turn cutting off normal prostate cell growth while permitting cancer to spread.

"Our study shows the underlying problem in prostate cancer is the presence of a gene fusion, not the androgen receptor," Chinnaiyan said in the news release. "In many contexts, androgen signaling is actually a good thing, but the presence of the gene fusion blocks androgen receptor signaling, which alters normal prostate cell development. While current treatments for advanced prostate cancer are focused on hormone deprivation and are quite effective, at least initially, future therapies need to be developed that target the prostate cancer gene fusion."

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.



-- Alan Mozes



SOURCE: Cancer Cell, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover the molecular heart of collective behavior
2. Scientists Map Genetic Codes of Human Microbes
3. Scientists find protein spurs spread of prostate cancer
4. What to Read on World Ocean Day: Scientists and Non Profits Herald New Eco-Thriller Eye of the Whale
5. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
6. Wistar scientists explain the persistence of melanoma through dynamic stemness
7. Mass. Eye and Ear receives NEI grant renewal for growing clinical/scientists
8. Scientists Map Neanderthal Genome
9. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
10. Scientists Unravel Secret of HIV Resistance
11. A century-old puzzle comes together: Scientists ID potential protein trigger in lung disease sarcoidosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story of ... the creation of published author, Larry R. Sherman, a retired chemistry professor from the ... as well as four novels. , Though the book opens in 1947, when ...
(Date:8/22/2017)... Carolina (PRWEB) , ... August 22, 2017 , ... ... advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership Development ... have become critical to his definition of “success”: physician leadership development, servant leadership, ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides an ... safety. By learning and implementing best practices for containment using ventilated safety enclosures, ... will gain a better understanding of a method for safely testing nanotechnology hoods. ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living ... Center. , Guests will be able to vote for their favorite Chef among ... with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive ... of Trustees for a three-year term beginning January 1, 2018. , The ... are committed to the improvement of health in their communities. Founded in 1898, the ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) today announced ... Aug. 7, 2017. ... and will serve as president emeritus during a planned, 90-day ... multiple leadership roles since he joined Diplomat with the acquisition ... decisive, strategic leadership which continues to benefit our patients and ...
(Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
Breaking Medicine Technology: